Zoetis Inc. (ZTS) Securities Class Action Lawsuit Update

• Company: Zoetis Inc. (NYSE: ZTS)
• Lead Plaintiff Deadline: July 27, 2026
• Class Period: January 14, 2025 - May 6, 2026
• Stock Drop: May 7, 2026 - ZTS fell $23.91 (21.5%) to $87.31; November 4, 2025 ZTS fell $19.89 (13.8%) to $124.46
• Lawsuit Type: Securities Class Action

Introduction

On May 27, 2026, a securities class action complaint was filed in the United States District Court for the Southern District of New York against Zoetis Inc. and two of its top executives. The lawsuit, captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., et al., alleges violations of the Securities Exchange Act of 1934 on behalf of all investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The defendants named in the complaint are Zoetis itself, Chief Executive Officer Kristin Peck, and Executive Vice President and Chief Financial Officer Wetteny Joseph.

Zoetis is a major animal health company, and the complaint alleges its Companion Animal segment, which accounted for roughly 70% of total revenue based on 2025 results, was central to its growth story. Throughout the class period, the complaint alleges Peck and Joseph made repeated optimistic statements about growing market share, veterinarian adoption, and expansion opportunities across key Companion Animal franchises. According to the complaint, investors allegedly purchased Zoetis securities at artificially inflated prices. Behind the curtain, however, the complaint alleges that a very different reality was taking hold. The complaint alleges veterinarians were becoming more cautious about prescribing Librela after the FDA flagged serious neurological events, including seizures and deaths in treated dogs. The complaint further alleges Elanco’s Zenrelia and Credelio Quattro were eroding Zoetis’ position in dermatology and parasiticides through lower pricing and broader or competing efficacy claims. The competitive moat Defendants described was eroding.

According to the complaint, the alleged truth emerged across four corrective disclosures spanning nearly a year. Weakening Companion Animal trends surfaced in August 2025, sending shares down 3.8%. A sharper drop of 13.8% followed in November 2025 when Zoetis cut its full-year outlook and acknowledged competitive pressure. Further deterioration emerged in February 2026. Then, on May 7, 2026, the dam broke: Zoetis reported first-quarter 2026 results showing significant deterioration across dermatology, parasiticides, and pain, slashed its guidance, and admitted that competition had "intensified across key pet care categories." Zoetis stock plummeted $23.91 per share, or 21.5%, to close at $87.31 on May 7, 2026, as the market absorbed the full extent of the deterioration that Defendants, the complaint alleges, knew or recklessly disregarded throughout the class period.

Backdrop and Business Context

Zoetis traces its origins to 1952, when Pfizer established an Animal Agriculture Division at its Vigo research facility in Terre Haute, Indiana, building on the success of the broad-spectrum antibiotic Terramycin. The division operated for decades as Pfizer Animal Health before Pfizer spun it off as an independent company. In February 2013, Zoetis completed its initial public offering on the New York Stock Exchange under the ticker ZTS, pricing shares at $26.00 apiece and raising approximately $2.2 billion. By mid-2013, Pfizer had fully divested its remaining stake, making Zoetis a standalone, publicly traded animal health company headquartered in Parsippany, New Jersey.

Zoetis develops, manufactures, and sells vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock across more than 100 countries. The company generates revenue primarily through prescription products sold to veterinarians, livestock producers, and pet owners, with companion animal products (dogs and cats) accounting for roughly 70% of total sales and livestock products (cattle, swine, poultry, fish, and sheep) making up nearly all of the remainder. In 2024, Zoetis reported $9.3 billion in annual revenue and employed approximately 13,800 people worldwide. Its key competitors include Elanco Animal Health, Merck Animal Health, and Boehringer Ingelheim Animal Health. Zoetis describes itself as a leading animal health company, and the complaint alleges its key Companion Animal franchises depended heavily on veterinarian confidence and willingness to prescribe.

Promises Made vs. Reality

The class period opened on January 14, 2025, at the JP Morgan Healthcare Conference, where CFO Wetteny Joseph positioned Zoetis as the "market leader" in dermatology, telling investors the company was "treating approximately 12 million dogs today for itch" while "13 million dogs globally that are medicalized" were "not receiving a prescription medicine for itch," with "substantial room to expand this market" underpinned by "a most differentiated set of products." On the same day, CEO Kristin Peck addressed the FDA's December 2024 "Dear Veterinarian" letter, which had described seizures, paresis, and deaths in dogs treated with Librela. In response to the FDA letter, Peck characterized it as “terribly helpful actually,” said it was consistent with what Zoetis had been telling investors, and said the company was “super excited” with Librela’s performance. Joseph reinforced confidence in competitive positioning, noting Simparica Trio had posted "25% growth" despite direct competition and asserting that "unless you have real differentiation, it makes it very, very hard to take over."

Over the ensuing months, Defendants escalated these assurances across multiple forums. During the Q4 2024 earnings call on February 13, 2025, Peck called Librela's U.S. launch "the most successful in our history" and claimed veterinarians "continue to intend to prescribe." She characterized the dermatology franchise as supported by "strong customer satisfaction, brand loyalty, and future long-acting formulation" that positioned Zoetis "to lead and expand the market." At the Bank of America Securities Animal Health Summit on February 27, 2025, Joseph described the Librela label update as "certainly not unexpected" and stated it had been "well-received from our customers." He reiterated at the Barclays Global Healthcare Conference on March 11, 2025, that veterinarian feedback was "very positive" and that dermatology still had "substantial opportunity to continue to expand." By the Q1 2025 earnings call on May 6, 2025, Joseph touted the Simparica franchise's 17% U.S. growth on $260 million in revenue and claimed "record penetration confirms that veterinarians want better OA solutions," while Peck highlighted a "40% share in puppies" and emphasized that "once one dog goes on a product, it's rare that it'll switch." Joseph told the BNP Paribas Animal Health Day audience on May 22, 2025, that veterinarian "satisfaction level with the products is very strong," and at the Stifel Jaws & Paws Conference on May 29, 2025, he boasted that Zoetis had risen "from fifth globally to second globally" in parasiticides. At the William Blair Growth Stock Conference on June 3, 2025, Joseph painted a picture of vast untapped market potential, noting that "only about a third" of 90 million U.S. dogs were "on prescription parasiticides" and claiming Zoetis "grew 25% in the first year of head-to-head competition."

Even after the first corrective disclosure on August 5, 2025, when weakening demand trends began surfacing, Defendants doubled down. They assured investors their "key franchises have significant runway for continued, durable growth," that Simparica Trio was "setting the standard of care," and that competitive activity was "often reinforcing our leadership." After the second disclosure on November 4, 2025, which drove ZTS down 13.8%, Defendants claimed the company's "resilient growth engine remains strong" and that its "trusted brands" continued "to lead their categories." Following the third disclosure on February 12, 2026, they maintained Zoetis was "competing from a position of strength" and that competitors were achieving only "very limited impact." As late as March 9, 2026, at the Leerlink Global Healthcare Conference, Joseph downplayed competition in parasiticides and claimed Librela was showing "stabilizing effects" based on veterinarian satisfaction levels.

As alleged in the complaint, these statements were materially false and misleading because Defendants knew or recklessly disregarded that veterinarian adoption of Librela was sharply weakening as clinicians grew cautious following the FDA's safety warnings about neurological complications; that Simparica Trio was losing significant market share to Elanco's lower-priced Credelio Quattro, which offered broader indicated use including tapeworm coverage; and that Apoquel and Cytopoint were losing substantial market share to Elanco's newly launched Zenrelia, marketed as comparable or superior to Apoquel in head-to-head clinical studies and at a lower price point.

Timeline of Alleged Misconduct and Disclosures

Class Period: January 14, 2025 - May 6, 2026, inclusive.

December 2024: The FDA issues a "Dear Veterinarian" letter describing severe adverse neurological events, including seizures, paresis, recumbency, urinary issues, and death or euthanasia outcomes in dogs treated with Librela.

January 14, 2025: Class period opens. At the JP Morgan Healthcare Conference, Defendant Joseph describes Zoetis as the "market leader" in dermatology and touts expansion potential. Defendant Peck characterizes the FDA's Dear Veterinarian letter as "terribly helpful" and expresses excitement about Librela's performance. Joseph downplays competitive risk to Simparica Trio.

February 13, 2025: Q4 2024 earnings call. Defendant Peck calls Librela's U.S. launch "the most successful in our history" and claims veterinarians "continue to intend to prescribe." She highlights 17% operational growth in dermatology and touts market expansion potential.

February 27, 2025: Bank of America Securities Animal Health Summit. Defendant Joseph describes Librela's label update as "certainly not unexpected" and "well-received" by customers.

March 11, 2025: Barclays Global Healthcare Conference. Defendant Joseph states veterinarian feedback on Librela has been "very positive" and highlights substantial opportunity in dermatology.

May 6, 2025: Q1 2025 earnings call. Defendant Joseph touts 17% U.S. growth for the Simparica franchise and "record penetration" for Librela. Defendant Peck highlights 40% puppy share for Simparica Trio.

May 22, 2025: BNP Paribas Animal Health Day. Defendant Joseph states Zoetis intends "to continue to lead" in dermatology and claims veterinarian satisfaction "is very strong."

May 29, 2025: Stifel Jaws & Paws Conference. Defendant Joseph claims Zoetis has risen from fifth to second globally in parasiticides.

June 3, 2025: William Blair Growth Stock Conference. Defendant Joseph touts vast expansion opportunity in parasiticides and claims 25% growth in the first year of head-to-head competition.

August 5, 2025: First alleged corrective disclosure. Zoetis releases Q2 2025 results revealing weakening demand in the Companion Animal portfolio, particularly in the pain franchise. ZTS drops $5.69 (3.8%) to $146.12. Defendants nevertheless reassure investors that "key franchises have significant runway for continued, durable growth" and that Simparica Trio is "setting the standard of care."

September 8, 2025: Morgan Stanley Global Healthcare Conference. Defendant Joseph claims Simparica Trio continues to gain share and that approximately 45% of the market is now triple combinations, with 60% of new puppies getting on triple combinations. Joseph expresses confidence Zoetis is "well-positioned to continue to lead" in dermatology.

November 4, 2025: Second alleged corrective disclosure. Zoetis releases Q3 2025 results showing slowing growth across key Companion Animal franchises and lowers its full-year sales outlook, disclosing continued Librela weakness and increased competitive pressure. ZTS drops $19.89 (13.8%) to $124.46. Defendants continue to claim the company's "resilient growth engine remains strong" and its "trusted brands" lead their categories.

February 12, 2026: Third alleged corrective disclosure. Zoetis releases Q4 and full-year 2025 results and provides 2026 guidance reflecting further slowing growth, acknowledging increasing competitive pressures in parasiticides and dermatology. ZTS drops $3.03 (2.35%) to $125.64. Defendants maintain Zoetis is "competing from a position of strength" and that competitors are having "very limited impact."

March 9, 2026: Leerlink Global Healthcare Conference. Defendant Joseph downplays competition in parasiticides and claims Librela is showing "stabilizing effects."

May 7, 2026: Fourth and final alleged corrective disclosure. Zoetis reports Q1 2026 results revealing significant deterioration across dermatology, parasiticides, and pain, and sharply reduces full-year guidance. The Company admits "competition intensified across key pet care categories," that "price has played a larger role in the decision process," and that "share loss is being amplified by a derm market with declining patient volume." ZTS plummets $23.91 (21.5%) to $87.31.

Investor Harm and Market Reaction

The most devastating single-day decline came on May 7, 2026, when Zoetis reported first-quarter 2026 results that, according to the complaint, revealed deterioration Defendants had allegedly concealed during the class period. ZTS plunged $23.91 per share, or 21.5%, closing at $87.31 on the day the Company admitted that competition had intensified across its key pet care categories and slashed its full-year guidance. The decline followed the Company's admission that "competition intensified across key pet care categories," that "price has played a larger role in the decision process," and that "share loss is being amplified by a derm market with declining patient volume," revelations that, according to the complaint, caused the prior artificial inflation to come out of the stock price.

According to the complaint, investor losses accumulated across multiple alleged corrective disclosures. On August 5, 2025, the first signs of weakness emerged when Q2 2025 results revealed unexpected softness in the Companion Animal portfolio, sending ZTS down $5.69, or 3.8%, to close at $146.12. Analysts zeroed in on the pain franchise and questioned long-term growth sustainability, even as Defendants attempted to reassure investors on the accompanying earnings call. The second disclosure on November 4, 2025, proved far more punishing: Zoetis lowered its full-year sales outlook and disclosed worsening trends across Librela, dermatology, and parasiticides. ZTS fell $19.89, or 13.8%, to close at approximately $124.46. A third disclosure on February 12, 2026, revealed further slowing growth and competitive pressure, pushing ZTS down another $3.03, or 2.35%, to $125.64.

Based on the complaint’s alleged stock-drop figures, ZTS declined by more than 40% from the mid-$150s before the first alleged corrective disclosure to $87.31 on May 7, 2026. The complaint alleges investors who purchased ZTS at artificially inflated prices suffered significant losses as the alleged truth emerged.

Litigation & Procedural Posture

The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against all Defendants, and under Section 20(a) of the Exchange Act against the Individual Defendants as controlling persons of Zoetis.

The defendants are Zoetis Inc., the animal health company; Kristin Peck, who served as CEO throughout the Class Period; and Wetteny Joseph, who served as Executive Vice President and CFO.

Scienter allegations center on the Individual Defendants' senior executive positions and their direct access to internal data on veterinarian adoption trends, competitive market share dynamics, and Librela prescription patterns, information that was available to them but not to the investing public. The complaint alleges that Peck and Joseph knew or recklessly disregarded that their public statements about growing market share, strong veterinarian satisfaction, and durable franchise performance were materially false when made. The complaint does not cite insider stock sales by the Individual Defendants or confidential witness testimony.

Procedurally, the case was filed on May 27, 2026, in the Southern District of New York. Lead plaintiff submissions are due by July 27, 2026. The proposed class encompasses all persons or entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, inclusive. At this early stage, the complaint seeks class certification, and the case remains in its initial pleading phase.

SEC Filings & Risk Factors

The complaint's allegations do not center on specific SEC periodic filings such as 10-K or 10-Q reports, but rather on the pattern of materially misleading statements made by the Individual Defendants at investor conferences and on earnings calls throughout the class period. These public forums, spanning from the JP Morgan Healthcare Conference on January 14, 2025, through the Leerlink Global Healthcare Conference on March 9, 2026, served as the primary vehicles through which Defendants allegedly misrepresented Zoetis' competitive positioning, veterinarian adoption trends, and growth sustainability.

The core disclosure failure, as alleged, was Defendants' repeated characterization of competitive dynamics as manageable or even beneficial, their portrayal of Librela's safety profile and veterinarian reception as positive and stabilizing, and their depiction of market share as growing across parasiticides and dermatology, when internal trends showed the opposite. Defendants used language designed to reassure: Simparica Trio was "setting the standard of care" and maintaining "first mover advantage"; Librela's label update was "certainly not unexpected" and "well-received"; and the dermatology franchise remained "durable" with "minimal patient share impact due to competition." The complaint alleges these characterizations were misleading in light of the Company’s operating trends, including declining Librela adoption, market-share losses in parasiticides, and erosion in dermatology.

The gap between Defendants' public representations and internal reality is underscored by the pattern of corrective disclosures. Each successive quarterly report revealed progressively worsening Companion Animal performance, yet Defendants continued to reassure investors between disclosures that the franchise was resilient and well-positioned. According to the complaint, the final alleged corrective disclosure revealed the extent of the issues allegedly concealed by prior statements. The complaint alleges the stock-price declines support materiality and loss causation because investors allegedly learned that Zoetis’ growth narrative was misleading.

How to Join the Zoetis Inc. (ZTS) Class Action

• Confirm you purchased ZTS shares during the January 14, 2025 to May 6, 2026 class period
• Review the allegations and eligibility requirements in the pending securities class action
• Gather trade confirmations and brokerage records documenting purchases or losses
• Consult counsel regarding lead plaintiff deadlines, eligibility, and recovery rights
• Click here to check eligibility

Disclaimer: Attorney Advertising. This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.